| Sarai Williams, OD | |
|
301 Burkesville St, Columbia, KY 42728-1921 | |
| (270) 384-6043 | |
| Not Available |
| Full Name | Sarai Williams |
|---|---|
| Gender | Female |
| Speciality | Optometry |
| Experience | 5 Years |
| Location | 301 Burkesville St, Columbia, Kentucky |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1730746173 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 2155DT (Kentucky) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Max M Downey Od Psc | 1254365570 | 3 |
News Archive
From how relationships affect our health to the psychology of an awkward party moment to why we often choose ignorance over information - a guide to some talks with new research in personality and social psychology at the APA Convention in Orlando, Aug. 2-5, 2012.
Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that its partner, ChronTech Pharma AB, has initiated a Phase IIb clinical study of its ChronVac-C DNA vaccine for hepatitis C virus, delivered by Inovio's proprietary electroporation DNA vaccine delivery technology, in combination with standard of care.
Chemokine Therapeutics has announced that it has been granted U.S. Patent No. 6,875,738 relating to the use of its anti-cancer compound, CTCE-9908, in the treatment of cancer and inhibition of angiogenesis. CTCE-9908 is designed to block CXCR4, a receptor found on the surface of cancer cells.
CytRx Corporation, a biopharmaceutical company, today announced that the Tumor Biology Center, Freiburg, Germany, plans to initiate a Phase 2 clinical trial with CytRx's doxorubicin prodrug INNO-206 as a treatment for patients with advanced pancreatic cancer.
› Verified 8 days ago
| Provider Name | Max M Downey Od Psc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1841253424 PECOS PAC ID: 1254365570 Enrollment ID: O20050926000316 |
News Archive
From how relationships affect our health to the psychology of an awkward party moment to why we often choose ignorance over information - a guide to some talks with new research in personality and social psychology at the APA Convention in Orlando, Aug. 2-5, 2012.
Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that its partner, ChronTech Pharma AB, has initiated a Phase IIb clinical study of its ChronVac-C DNA vaccine for hepatitis C virus, delivered by Inovio's proprietary electroporation DNA vaccine delivery technology, in combination with standard of care.
Chemokine Therapeutics has announced that it has been granted U.S. Patent No. 6,875,738 relating to the use of its anti-cancer compound, CTCE-9908, in the treatment of cancer and inhibition of angiogenesis. CTCE-9908 is designed to block CXCR4, a receptor found on the surface of cancer cells.
CytRx Corporation, a biopharmaceutical company, today announced that the Tumor Biology Center, Freiburg, Germany, plans to initiate a Phase 2 clinical trial with CytRx's doxorubicin prodrug INNO-206 as a treatment for patients with advanced pancreatic cancer.
› Verified 8 days ago
| Provider Name | Downey Eye Clinic Pllc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1841253424 PECOS PAC ID: 9830561117 Enrollment ID: O20231204003000 |
News Archive
From how relationships affect our health to the psychology of an awkward party moment to why we often choose ignorance over information - a guide to some talks with new research in personality and social psychology at the APA Convention in Orlando, Aug. 2-5, 2012.
Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that its partner, ChronTech Pharma AB, has initiated a Phase IIb clinical study of its ChronVac-C DNA vaccine for hepatitis C virus, delivered by Inovio's proprietary electroporation DNA vaccine delivery technology, in combination with standard of care.
Chemokine Therapeutics has announced that it has been granted U.S. Patent No. 6,875,738 relating to the use of its anti-cancer compound, CTCE-9908, in the treatment of cancer and inhibition of angiogenesis. CTCE-9908 is designed to block CXCR4, a receptor found on the surface of cancer cells.
CytRx Corporation, a biopharmaceutical company, today announced that the Tumor Biology Center, Freiburg, Germany, plans to initiate a Phase 2 clinical trial with CytRx's doxorubicin prodrug INNO-206 as a treatment for patients with advanced pancreatic cancer.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sarai Williams, OD 301 Burkesville St, Columbia, KY 42728-1921 Ph: (270) 384-6043 | Sarai Williams, OD 301 Burkesville St, Columbia, KY 42728-1921 Ph: (270) 384-6043 |
News Archive
From how relationships affect our health to the psychology of an awkward party moment to why we often choose ignorance over information - a guide to some talks with new research in personality and social psychology at the APA Convention in Orlando, Aug. 2-5, 2012.
Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that its partner, ChronTech Pharma AB, has initiated a Phase IIb clinical study of its ChronVac-C DNA vaccine for hepatitis C virus, delivered by Inovio's proprietary electroporation DNA vaccine delivery technology, in combination with standard of care.
Chemokine Therapeutics has announced that it has been granted U.S. Patent No. 6,875,738 relating to the use of its anti-cancer compound, CTCE-9908, in the treatment of cancer and inhibition of angiogenesis. CTCE-9908 is designed to block CXCR4, a receptor found on the surface of cancer cells.
CytRx Corporation, a biopharmaceutical company, today announced that the Tumor Biology Center, Freiburg, Germany, plans to initiate a Phase 2 clinical trial with CytRx's doxorubicin prodrug INNO-206 as a treatment for patients with advanced pancreatic cancer.
› Verified 8 days ago
Downey Eye Clinic Optometrist Medicare: Not Enrolled in Medicare Practice Location: 301 Burkesville St, Columbia, KY 42728 Phone: 270-384-6043 Fax: 270-384-0672 | |
Dr. Jacob Burton, O.D Optometrist Medicare: Accepting Medicare Assignments Practice Location: 301 Burkesville Street, Columbia, KY 42728 Phone: 270-384-6043 Fax: 270-384-0672 | |
Dr. Max Mitchell Downey, OD Optometrist Medicare: Medicare Enrolled Practice Location: 301 Burkesville St, Columbia, KY 42728 Phone: 270-384-6043 Fax: 270-384-0672 | |
Kerr Eye Care Pllc Optometrist Medicare: Medicare Enrolled Practice Location: 2988 Burkesville Rd, Suite 160, Columbia, KY 42728 Phone: 270-384-4444 | |
Downey Eye Clinic Optometrist Medicare: Medicare Enrolled Practice Location: 301 Burkesville St, Columbia, KY 42728 Phone: 270-384-6043 Fax: 270-384-0672 |